Stock Scorecard
Stock Summary for Arcutis Biotherapeutics Inc (ARQT) - $25.37 as of 1/30/2026 7:28:08 PM EST
Total Score
6 out of 30
Safety Score
42 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ARQT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ARQT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ARQT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ARQT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ARQT (42 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for ARQT
Company Overview |
|
|---|---|
| Ticker | ARQT |
| Company Name | Arcutis Biotherapeutics Inc |
| Country | USA |
| Description | Arcutis Biotherapeutics, Inc. is a leading biopharmaceutical company based in California, focused on pioneering innovative therapies for dermatological conditions with considerable unmet medical needs. The company boasts a robust pipeline of promising treatments designed to improve patient outcomes in skin health, thereby positioning itself strategically within the expanding dermatology market. Leveraging cutting-edge research and strategic partnerships, Arcutis is well-equipped for significant growth, making it an intriguing investment opportunity for institutional investors seeking exposure in the life sciences sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/24/2026 |
Stock Price History |
|
| Last Day Price | 25.37 |
| Price 4 Years Ago | 14.80 |
| Last Day Price Updated | 1/30/2026 7:28:08 PM EST |
| Last Day Volume | 929,185 |
| Average Daily Volume | 1,673,770 |
| 52-Week High | 31.77 |
| 52-Week Low | 11.13 |
| Last Price to 52 Week Low | 127.94% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 15.77 |
| Sector PE | 95.54 |
| 5-Year Average PE | -18.05 |
| Free Cash Flow Ratio | 66.76 |
| Industry Free Cash Flow Ratio | 10.28 |
| Sector Free Cash Flow Ratio | 26.23 |
| Current Ratio Most Recent Quarter | 3.50 |
| Total Cash Per Share | 0.38 |
| Book Value Per Share Most Recent Quarter | 1.31 |
| Price to Book Ratio | 19.72 |
| Industry Price to Book Ratio | 51.55 |
| Sector Price to Book Ratio | 22.01 |
| Price to Sales Ratio Twelve Trailing Months | 9.91 |
| Industry Price to Sales Ratio Twelve Trailing Months | 32.20 |
| Sector Price to Sales Ratio Twelve Trailing Months | 18.97 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 122,492,000 |
| Market Capitalization | 3,107,622,040 |
| Institutional Ownership | 108.01% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 46.58% |
| Reported EPS 12 Trailing Months | -0.34 |
| Reported EPS Past Year | -0.27 |
| Reported EPS Prior Year | -1.16 |
| Net Income Twelve Trailing Months | -44,324,000 |
| Net Income Past Year | -140,039,000 |
| Net Income Prior Year | -262,140,000 |
| Quarterly Revenue Growth YOY | 121.70% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 8.59% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 47,120,000 |
| Total Cash Past Year | 71,335,000 |
| Total Cash Prior Year | 88,398,000 |
| Net Cash Position Most Recent Quarter | -60,378,000 |
| Net Cash Position Past Year | -35,868,000 |
| Long Term Debt Past Year | 107,203,000 |
| Long Term Debt Prior Year | 201,799,000 |
| Total Debt Most Recent Quarter | 107,498,000 |
| Equity to Debt Ratio Past Year | 0.60 |
| Equity to Debt Ratio Most Recent Quarter | 0.60 |
| Total Stockholder Equity Past Year | 157,541,000 |
| Total Stockholder Equity Prior Year | 88,667,000 |
| Total Stockholder Equity Most Recent Quarter | 158,073,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -38,244,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.31 |
| Free Cash Flow Past Year | -112,301,000 |
| Free Cash Flow Prior Year | -247,485,000 |
Options |
|
| Put/Call Ratio | 0.16 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.72 |
| MACD Signal | -0.55 |
| 20-Day Bollinger Lower Band | 16.59 |
| 20-Day Bollinger Middle Band | 25.14 |
| 20-Day Bollinger Upper Band | 33.69 |
| Beta | 1.72 |
| RSI | 38.95 |
| 50-Day SMA | 18.57 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/30/2026 5:34:50 PM EST |